TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31174494

Group type: EXPERIMENTAL
Intervention: Mobile phone app-based cognitive behaviour training (CBT) for 6 weeks, with weekly theme modules including learning content and assignments.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual postpartum care content through the App.
Number of subjects: 120
Study: 29742990

Group type: EXPERIMENTAL
Intervention: MVPA%SOFIT estimates from direct observation protocols
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MVPA%perm estimates based on permutations of students and observation order
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Differences in MVPA% estimates between randomly selected groups of lessons
Number of subjects: 35
Study: 26962852

Group type: EXPERIMENTAL
Intervention: Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc)
Number of subjects: 62
Study: 25152290

Group type: EXPERIMENTAL
Intervention: Coopdech bronchial blocker (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-lumen tube (group B)
Number of subjects: 40
Study: 22873532

Group type: EXPERIMENTAL
Intervention: R-FC (rituximab, fludarabine, and cyclophosphamide)
Number of subjects: 560

Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Rituximab (maintenance therapy)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Interferon alfa (maintenance therapy)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: R-CHOP followed by rituximab maintenance
Number of subjects: 560

Group type: COMPARATOR
Intervention: R-CHOP followed by interferon alfa maintenance
Number of subjects: 560
Study: 21209539

Group type: EXPERIMENTAL
Intervention: Volume preload of 1000 ml of Ringer's lactate solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: No volume preload
Number of subjects: 40
Study: 17116398

Group type: EXPERIMENTAL
Intervention: Transcervical extended mediastinal lymphadenectomy (TEMLA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cervical mediastinoscopy (CM)
Number of subjects: 41
Study: 15657860

Group type: EXPERIMENTAL
Intervention: Precut papillotomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Persistence with non-wire-guided, single-lumen papillotome
Number of subjects: 62
Study: 12405614

Group type: EXPERIMENTAL
Intervention: Participants with chronic low back pain (CLBP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nondepressed participants with CLBP
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Depressed participants with CLBP
Number of subjects: 21
Study: 11578786

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 6906

Group type: COMPARATOR
Intervention: Standard enucleation
Number of subjects: 6906
Study: 9556921

Group type: EXPERIMENTAL
Intervention: Dynamic Posturography (DP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Randomized Perturbed Posturography (RPP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Movement Coordination (MC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 14
Study: 7569625

Group type: EXPERIMENTAL
Intervention: Chagas' infection (serologic evidence)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Chagas' infection (with EKG alterations)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Negative serologic test (with EKG alterations)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Chagas' infection (intraventricular conduction defects)
Number of subjects: 372
Study: 2691479

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (1,000 mg amoxycillin + 250 mg clavulanate) tds
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg) bd
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 1101707

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 6154334

Group type: EXPERIMENTAL
Intervention: Hypothermic cardioplegic solution (200-1000 ml) infused into the ascending aorta during cardiopulmonary bypass.
Number of subjects: 41
Study: 31764793

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (1 mg, 4 ml) for 15 minutes before bronchoscopy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 29688425

Group type: EXPERIMENTAL
Intervention: PST (grazed perennial crested wheatgrass and native range before feedlot entry)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: ANN (grazed perennial crested wheatgrass and native range, then field pea-barley mix and unharvested corn before feedlot entry)
Number of subjects: 144

Group type: COMPARATOR
Intervention: FLT (feedlot)
Number of subjects: 144
Study: 26946208

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliances (MAAs) used for 12 consecutive months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intraoral device or treatment)
Number of subjects: 28
Study: 25231382

Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX) fiber
Number of subjects: 12
Study: 22714779

Group type: EXPERIMENTAL
Intervention: Topical (S)-ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19596382

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a sc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1b sc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-beta 1a im
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glatiramer acetate
Number of subjects: 0
Study: 18044287

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Alfentanil 20 microg/kg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Fentanyl 2 microg/kg
Number of subjects: 69
Study: 16225527

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (1.3, 2.6, and 3.9 mg/day)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (3.9 mg/day)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Extended-release tolterodine (4 mg/day)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: 3-day diaries
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: 7-day diaries
Number of subjects: 881
Study: 11805650

Group type: EXPERIMENTAL
Intervention: Active straight leg raise
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Active straight leg raise with manual compression through the ilia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (pain-free subjects)
Number of subjects: 26
Study: 10068415

Group type: EXPERIMENTAL
Intervention: Daily intravenous infusion of 60 microg of prostaglandin E1 (alprostadil‐alpha‐cyclodextrine)
Number of subjects: 1560

Group type: COMPARATOR
Intervention: No prostaglandin E1
Number of subjects: 1560
Study: 7782873

Group type: EXPERIMENTAL
Intervention: Professional development program for Clinical Nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1959538

Group type: EXPERIMENTAL
Intervention: rHuEPO at 10 units/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: rHuEPO at 100 units/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: rHuEPO (all doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: rHuEPO at 25-50 units/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: rHuEPO (doses greater than 25 units/kg)
Number of subjects: 16
Study: 6955123

Group type: EXPERIMENTAL
Intervention: Professional toothcleaning every 2 weeks for 18 months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction and practice in proper toothcleaning techniques
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 104
Study: 31820002

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Health Education (HE)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 255
Study: 31275984

Group type: EXPERIMENTAL
Intervention: IT > 10 Ncm (G1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: IT ≥ 10Ncm and ≤ 30 Ncm (G2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: IT >30Ncm and < 45Ncm (G3)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: IT ≥ 45Ncm (G4)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 31
Study: 29984430

Group type: EXPERIMENTAL
Intervention: Mystery shop intervention with monthly feedback to clerks and servers.
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Mystery shop intervention for on-premises establishments.
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Mystery shop intervention for off-premises establishments.
Number of subjects: 557
Study: 26796803

Group type: EXPERIMENTAL
Intervention: CAPOX regimen
Number of subjects: 107

Group type: COMPARATOR
Intervention: SOX regimen
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: CAPOX regimen in TP-positive patients
Number of subjects: 107

Group type: COMPARATOR
Intervention: SOX regimen in DPD-positive patients
Number of subjects: 107
Study: 24525690

Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg daily for 12 weeks)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 22357383

Group type: EXPERIMENTAL
Intervention: Descemet stripping endothelial keratoplasty (DSEK)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty
Number of subjects: 69

Group type: COMPARATOR
Intervention: Normal corneas (control group)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Corneas without visible subbasal nerves (after DSEK)
Number of subjects: 69
Study: 20660020

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 17
Study: 17660186

Group type: EXPERIMENTAL
Intervention: Epoetin delta
Number of subjects: 560

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 560
Study: 15718405

Group type: EXPERIMENTAL
Intervention: ACTN3 577X genotype (XX)
Number of subjects: 355

Group type: COMPARATOR
Intervention: ACTN3 wild type (RR)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: ACTN3 genotype
Number of subjects: 355
Study: 12131931

Group type: EXPERIMENTAL
Intervention: Clonazepam 2 mg/day for 6 weeks
Number of subjects: 18
Study: 9924158

Group type: EXPERIMENTAL
Intervention: Heparin treatment to maintain activated clotting time of >300 seconds
Number of subjects: 39
Study: 7593733

Group type: EXPERIMENTAL
Intervention: Moclobemide treatment
Number of subjects: 651
Study: 2271264

Group type: EXPERIMENTAL
Intervention: False positive results group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (negative test results)
Number of subjects: 56
Study: 368535

Group type: EXPERIMENTAL
Intervention: ibuprofen 1600 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: indomethacin 100 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: indomethacin and ibuprofen
Number of subjects: 20
Study: 31854221

Group type: EXPERIMENTAL
Intervention: Transverse incision along the distal border of the pronator quadratus (Group A)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Brachioradialis splitting method (Group B)
Number of subjects: 110
Study: 30345954

Group type: EXPERIMENTAL
Intervention: DentalVibe
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Manual stimulation
Number of subjects: 150

Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 150
Study: 27919222

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch (30 min) plus SOC
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch (60 min) plus SOC
Number of subjects: 468

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 468
Study: 22206410

Group type: EXPERIMENTAL
Intervention: Butorphanol, midazolam, dexmedetomidine (BMD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Butorphanol, midazolam, propofol (BMP)
Number of subjects: 40
Study: 21887594

Group type: EXPERIMENTAL
Intervention: Experimental diet containing 600 g/kg DM of wheat middlings (WM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet containing 400 g/kg DM of corn
Number of subjects: 40
Study: 21034938

Group type: EXPERIMENTAL
Intervention: Second-look procedures (SLP) before completing chemotherapy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Second-look procedures (SLP) during treatment
Number of subjects: 73

Group type: COMPARATOR
Intervention: No second-look procedures (SLP) during treatment
Number of subjects: 73
Study: 18551889

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg daily for 3 days prior to quit date, then 50 mg daily for 8 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 16156143

Group type: EXPERIMENTAL
Intervention: Intracameral injection of 2% hydroxypropyl methylcellulose (HPMC) during trabeculectomy (group II; n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional trabeculectomy without HPMC injection (group I; n = 15)
Number of subjects: 30
Study: 12116727

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo control (containing copolymer)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (in subgroup with >= 40 bleeding sites)
Number of subjects: 160
Study: 11081003

Group type: EXPERIMENTAL
Intervention: Fibro-Fit program (interdisciplinary group education and exercise program with 36 sessions over 12 weeks)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Fibro-Fit program
Number of subjects: 149
Study: 8826928

Group type: EXPERIMENTAL
Intervention: Good steroid response
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: T-ALL treatment protocols (8303, 8503-8703, and '88)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: T-ALL patients
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Poor in vivo steroid response
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Leukocyte level count > 50 x 10^9/l
Number of subjects: 184
Study: 2124962

Group type: EXPERIMENTAL
Intervention: Penicillin V 1000 mg once daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: Penicillin V 250 mg four times daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: Penicillin V 500 mg twice daily
Number of subjects: 142
Study: 6770291

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study: 31164178

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 28535624

Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography (EIT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: EIT combined with Ultrasound
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: EIT combined with Mammography
Number of subjects: 121
Study: 24983892

Group type: EXPERIMENTAL
Intervention: N-DMT intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 19
Study: 23190588

Group type: COMPARATOR
Intervention: Diet modification (N = 118)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Aerobic exercise (N = 117)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Diet + exercise (N = 117)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control (N = 87)
Number of subjects: 439
Study: 21518711

Group type: EXPERIMENTAL
Intervention: Multimedia permission/assent process
Number of subjects: 194

Group type: COMPARATOR
Intervention: Paper permission/assent process
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Multimedia parental permission/assent process
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Video version of dual-energy radiograph absorptiometry description
Number of subjects: 194

Group type: COMPARATOR
Intervention: Animated and paper versions combined for dual-energy radiograph absorptiometry description
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Multimedia abdominal ultrasound description
Number of subjects: 194

Group type: COMPARATOR
Intervention: Animated and paper versions combined for abdominal ultrasound description
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Understanding of study procedures
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Understanding of risks
Number of subjects: 194
Study: 19389417

Group type: EXPERIMENTAL
Intervention: Sustained convergence for 5 minutes
Number of subjects: 0
Study: 16516602

Group type: EXPERIMENTAL
Intervention: Quinapril at a target dose of 60 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 14722602

Group type: EXPERIMENTAL
Intervention: Audiotapes
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no audiotapes)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 11095454

Group type: EXPERIMENTAL
Intervention: Hydrocortisone at bedtime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9050888

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (oral administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSH deficiency in CD4 T cells
Number of subjects: 0
Study: 7914959

Group type: EXPERIMENTAL
Intervention: Cuprophane membranes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Polyacrylonitrile membranes
Number of subjects: 52
Study: 3056288

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (34.5 Gy, divided into 15 daily doses of 2.3 Gy each)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control group (no preoperative radiotherapy)
Number of subjects: 466
Study: 28885279

Group type: EXPERIMENTAL
Intervention: reduced Cardiac Rehabilitation Program (rCRP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: standard Cardiac Rehabilitation Program (sCRP)
Number of subjects: 121
Study: 26201299

Group type: EXPERIMENTAL
Intervention: Cabotegravir 10 mg once a day
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg once a day
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cabotegravir 60 mg once a day
Number of subjects: 243

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once a day with dual NRTIs
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cabotegravir (all doses combined)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Efavirenz (control)
Number of subjects: 243
Study: 23592605

Group type: EXPERIMENTAL
Intervention: 6 mg ropivacaine + 5 µg sufentanil
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine + 5 µg sufentanil
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine + 5 µg sufentanil
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 12 mg ropivacaine + 5 µg sufentanil
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All doses of ropivacaine
Number of subjects: 68
Study: 20872345

Group type: EXPERIMENTAL
Intervention: Pulse high-volume hemofiltration (PHVHF) for 72 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 22
Study: 17707902

Group type: EXPERIMENTAL
Intervention: Adolescents of HIV-infected mothers
Number of subjects: 105

Group type: COMPARATOR
Intervention: Adolescents of HIV-uninfected mothers
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups of adolescents
Number of subjects: 105
Study: 16651301

Group type: EXPERIMENTAL
Intervention: HPV Information Sheet
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control group (baseline paragraph about HPV)
Number of subjects: 1600
Study: 12783932

Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nonrandomized control groups (ER-negative breast cancer and additional ER-positive breast cancer)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamoxifen (all doses)
Number of subjects: 120
Study: 10963196

Group type: EXPERIMENTAL
Intervention: Magnetic resonance cholangiopancreatography (MRCP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 124
Study: 8916481

Group type: EXPERIMENTAL
Intervention: 3 weeks of exercise training (interval exercise with bicycle ergometer 15 minutes 5 times weekly, interval treadmill walking 10 minutes, and exercises 20 minutes, each 3 times weekly)
Number of subjects: 18
Study: 1760710

Group type: EXPERIMENTAL
Intervention: Carrying 5 kg or more weights
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carrying 10 kg weights
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mild claudicants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Severe claudicants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weight carried (0, 2.5, 5, 7.5, 10 kg)
Number of subjects: 20
Study: 7064017

Group type: EXPERIMENTAL
Intervention: Doxorubicin (40 mg/m2) and cyclophosphamide (700 mg/m2) administered as pulse doses once every 3 weeks.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Celestin tubes insertion (all patients).
Number of subjects: 24
Study: 31927549

Group type: EXPERIMENTAL
Intervention: Group TPVB (20 mL of 0.25% ropivacaine)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Group LAI (40 mL of 0.25% ropivacaine)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Group TPVB
Number of subjects: 74

Group type: COMPARATOR
Intervention: Group LAI
Number of subjects: 74
Study: 30859959

Group type: EXPERIMENTAL
Intervention: Lumateperone 60mg (ITI-007)
Number of subjects: 1783

Group type: EXPERIMENTAL
Intervention: Lumateperone 40mg (ITI-007)
Number of subjects: 1783

Group type: EXPERIMENTAL
Intervention: Lumateperone 20mg (ITI-007)
Number of subjects: 1783

Group type: COMPARATOR
Intervention: Risperidone 4mg (active control)
Number of subjects: 1783

Group type: EXPERIMENTAL
Intervention: Lumateperone (open-label safety switching study)
Number of subjects: 1783

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) antipsychotics
Number of subjects: 1783
Study: 28914245

Group type: EXPERIMENTAL
Intervention: Antioxidant mix
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 40